Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Borthakur, Gautam  [Clear All Filters]
2019
Ravandi, F., Assi, R., Daver, N., Benton, C.B., Kadia, T., Thompson, P.A., Borthakur, G., Alvarado, Y., Jabbour, E.J., Konopleva, M., et al. (2019). Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.Lancet Haematol.
Tallis, E., and Borthakur, G. (2019). Novel treatments for relapsed/refractory acute myeloid leukemia with mutations.Expert Rev Hematol.
2016
Jain, N., Lamb, A.E., O'Brien, S., Ravandi, F., Konopleva, M., Jabbour, E., Zuo, Z., Jorgensen, J., Lin, P., Pierce, S., et al. (2016). Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype.Blood.
2015
Oran, B., Jimenez, A.M., de Lima, M., Popat, U.R., Bassett, R., Andersson, B., Borthakur, G., Bashir, Q., Chen, J., Ciurea, S.O., et al. (2015). Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation.Biol Blood Marrow Transplant.
Takahashi, K., Kantarjian, H., Garcia-Manero, G., Borthakur, G., Kadia, T., DiNardo, C., Jabbour, E., Pierce, S., Estrov, Z., Konopleva, M., et al. (2015). Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients.Clin Lymphoma Myeloma Leuk.
Daver, N., Thomas, D., Ravandi, F., Cortes, J., Garris, R., Jabbour, E., Garcia-Manero, G., Borthakur, G., Kadia, T., Rytting, M., et al. (2015). Final report of a phase II study of imatinib mesylate with hyper-CVAD for the frontline treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia.Haematologica.
Ravandi, F., Jorgensen, J.L., O'Brien, S.M., Jabbour, E., Thomas, D.A., Borthakur, G., Garris, R., Huang, X., Garcia-Manero, G., Burger, J.A., et al. (2015). Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia.Br J Haematol.
Sasaki, K., Strom, S.S., O'Brien, S., Jabbour, E., Ravandi, F., Konopleva, M., Borthakur, G., Pemmaraju, N., Daver, N., Jain, P., et al. (2015). Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials.Lancet Haematol2, e186-93.
2014
Zhang, W., Gao, C., Konopleva, M., Chen, Y., Jacamo, R., Borthakur, G., Cortes, J.E., Ravandi-Kashani, F., Ramachandran, A., and Andreeff, M. (2014). Reversal of Acquired Drug Resistance in FLT3-mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies.Clin Cancer Res.
2013
Strati, P., Kantarjian, H., Thomas, D., O'Brien, S., Konoplev, S., Jorgensen, J.L., Luthra, R., Abruzzo, L., Jabbour, E., Quintas-Cardama, A., et al. (2013). HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia.Cancer.